Comparison of immunological abnormalities of lymphocytes in bone marrow in myelodysplastic syndrome (MDS) and aplastic anemia (AA)

Internal Medicine

Volumn 49, Issue 14, 2010, Pages 1349-1355

  Li, Xiao ^a   Xu, Feng ^a   He, Qi ^a   Wu, Lingyun ^a   Zhang, Zheng ^a   Chang, Chunkang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

Aplastic anemia; Lymphocytes; Myelodysplastic syndromes; Polarization; T cell subsets

Indexed keywords

CD19 ANTIGEN;

ADOLESCENT; ADULT; AGED; APLASTIC ANEMIA; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POLARITY; CELLULAR DISTRIBUTION; CHILD; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HIGH RISK PATIENT; HUMAN; IMMUNE STATUS; IMMUNOLOGICAL MONITORING; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; MALE; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; POLARIZATION; RISK ASSESSMENT; SCHOOL CHILD; SCORING SYSTEM; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA, APLASTIC; BONE MARROW; CHILD; CHROMOSOME ABERRATIONS; FEMALE; HUMANS; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; YOUNG ADULT;

EID: 77954988521     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.3477     Document Type: Article

References (25)

1. Wu L, Li X, Chang C, Ying S, He Q, Pu Q. Deviation of type I and type II T cells and its negative effect on hematopoiesis in myelodysplastic syndrome. Int J Lab Hematol 30: 390-399, 2008.
2. Suda H, Yamasaki H. Type I and type II T-cell profiles in aplastic anemia and refractory anemia. Am J Hematol 64: 271-274, 2000.
3. Melenhorst JJ, Eniafe R, Follmann D. Molecular and flow cytometric characterization of the CD4 and CD8 T-cell repertoire in patients with myelodysplastic syndrome. Br J Haematol 119: 97-105, 2002.
4. Baumann I, Scheid C, Koref MS, Swindell R, Stern P, Testa NG. Autologous lymphocytes inhibit emopoiesis in long-term culture in patients with myelodysplastic syndrome. Exp Hematol 30: 1405-1411, 2002.
5. Lima M, Teixeira Mdos A, Queirós ML. Immunophenotype and TCR-Vbeta repertoire of peripheral blood T-cells in acute infectious mononucleosis. Blood Cells Mol Dis 30: 1-12, 2003.
6. Epperson DE, Nakamura R, Saunthararajah Y. Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leuk Res 25: 1075-1083, 2001.
7. Lim ZY, Killick S, Germing U, et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia 21: 1436-1441, 2007.
8. Steensma DP, Dispenzieri A, Moore SB, Schroeder G, Tefferi A. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood 101: 2156-2158, 2003.
9. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 108: 2509-2519, 2006.
10. Nakao S, Takami A, Takamatsu H, et al. Isolation of a T-cell clone showing HLA-DRB1* 0405-restricted cytotoxicity for hematopoietic cells in a patient with aplastic anemia. Blood 89: 3691-3699, 1997.
11. Maciejewski JP, Risitano A, Kook H, Zeng W, Chen G, Young NS. Immune pathophysiology of aplastic anemia. Int J Hematol 76: 207-214, 2002.
12. Camitta BM. Aprospective study of androgen and bone marrow transplantation on treatment of severe aplastic anemia. Blood 53: 504, 1979.
13. Gordon-Smith EC. Management of aplastic anemia. Br J Haematol 53: 185, 1983.
14. Hoffman R, Benz JE, Cohen SJ. Hematology-basic Principles and Practice. 3rd ed. Harcourt Asia PTE. Ltd, 2001: 342.
15. British Society for Haematology. Guidelines for the diagnosis and management of aquired aplastic anemia. Br J Haematol 123: 782-801, 2003.
16. Greenberg P, Cox C, LeBeau MM, et al. International prognosis scoring system (IPSS) for evaluating prognosis in myelodysplastic syndrome. Blood 89: 2079-2088, 1997.
17. Harris N, Jaffe E, Diebold J. WHO classification of neoplastic diseases of the hematopietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Article House, Virginia. J Clin Oncol 17: 3835-3849, 1997.
18. Jung T, Schauer U, Heuser C, et al. Detection of intracellular cytokines by flow cytometry. J Immunol Meth 159: 197-207, 1993.
19. Ogata K, Kishikawa Y, Satoh C, Tamura H, Dan K, Hayashi A. Diagnostic application of flow cytometric characteristics of CD 34+ cells in low-grade myelodysplastic syndromes. Blood 108: 1037-1044, 2006.
20. Sternberg A, Killick S, Littlewood T, et al. Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome. Blood 106: 2982-2991, 2005.
21. Matsui WH, Brodsky RA, Smith BD, Borowitz MJ, Jones RJ. Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes. Leukemia 20: 458-462, 2006.
22. Hirano N, Butler MO, von Bergwelt-Baildon MS, et al. Autoantibodies frequently detected in patients with aplastic anemia. Blood 102: 4567-4575, 2003.
23. Feng X, Chuhjo T, Sugimori C, et al. Diazepambinding inhibitorrelated protein 1: a candidate autoantigen in acquired aplastic ane mia patients harboring a minor populatoin of paroxysmal nocturnal hemoglobinuria-type cells. Blood 104: 2425-2431, 2004.
24. Maciejewski JP, Risitano AM, Sloand EM, Nunez O, Young NS. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood 99: 3129-3135, 2002.
25. Barrett AJ, Sloand E. Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance. Haematologica 94: 449-451, 2009.